Approval Summary: Imatinib Mesylate for One or Three Years in the Adjuvant Treatment of Gastrointestinal Stromal Tumors

On January 31, 2012, the U.S. Food and Drug Administration granted regular approval of imatinib mesylate tablets (Gleevec®; Novartis Pharmaceuticals Corporation, East Hanover, NJ) for the adjuvant treatment of adult patients following complete gross resection of Kit(+) (CD117(+)) gastrointestinal st...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Hauptverfasser: Cohen, Martin H., Johnson, John R., Justice, Robert, Pazdur, Richard
Format: Artigo
Sprache:Inglês
Veröffentlicht: AlphaMed Press 2012
Schlagworte:
Regulatory Issues: FDA
Online Zugang:https://ncbi.nlm.nih.gov/pmc/articles/PMC3399657/
https://ncbi.nlm.nih.gov/pubmed/22643537
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1634/theoncologist.2012-0109
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!

Ähnliche Einträge